Tülin Budak-Alpdoǧan

1.3k total citations
51 papers, 970 citations indexed

About

Tülin Budak-Alpdoǧan is a scholar working on Molecular Biology, Oncology and Hematology. According to data from OpenAlex, Tülin Budak-Alpdoǧan has authored 51 papers receiving a total of 970 indexed citations (citations by other indexed papers that have themselves been cited), including 23 papers in Molecular Biology, 23 papers in Oncology and 20 papers in Hematology. Recurrent topics in Tülin Budak-Alpdoǧan's work include Multiple Myeloma Research and Treatments (10 papers), CAR-T cell therapy research (8 papers) and Immune Cell Function and Interaction (8 papers). Tülin Budak-Alpdoǧan is often cited by papers focused on Multiple Myeloma Research and Treatments (10 papers), CAR-T cell therapy research (8 papers) and Immune Cell Function and Interaction (8 papers). Tülin Budak-Alpdoǧan collaborates with scholars based in United States, Türkiye and Italy. Tülin Budak-Alpdoǧan's co-authors include Joseph R. Bertino, Debabrata Banerjee, Philipp Mayer‐Kuckuk, Richard Görlick, Önder Alpdoğan, Mahmut Bayık, Manoj K. Pandey, Isabelle Rivière, Michel Sadelain and Siret Ratıp and has published in prestigious journals such as SHILAP Revista de lepidopterología, Blood and Nature Biotechnology.

In The Last Decade

Tülin Budak-Alpdoǧan

47 papers receiving 950 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Tülin Budak-Alpdoǧan United States 18 430 310 221 187 149 51 970
John Marken United States 9 607 1.4× 294 0.9× 587 2.7× 280 1.5× 250 1.7× 13 1.5k
Alessandro Canella Italy 21 607 1.4× 273 0.9× 122 0.6× 239 1.3× 59 0.4× 52 1.2k
Frédéric Barabé Canada 20 732 1.7× 286 0.9× 416 1.9× 348 1.9× 78 0.5× 38 1.3k
Rosa Di Noto Italy 21 517 1.2× 207 0.7× 377 1.7× 210 1.1× 40 0.3× 43 1.1k
Xiaojian Zhu China 18 535 1.2× 426 1.4× 162 0.7× 163 0.9× 99 0.7× 68 959
Emma F. Barry Australia 14 360 0.8× 346 1.1× 274 1.2× 396 2.1× 57 0.4× 18 942
Yataro Yoshida Japan 18 404 0.9× 177 0.6× 664 3.0× 204 1.1× 131 0.9× 85 1.1k
S. Danhauser-Riedl Germany 15 392 0.9× 347 1.1× 422 1.9× 237 1.3× 73 0.5× 34 1.1k
Weili Zhao China 21 485 1.1× 336 1.1× 127 0.6× 254 1.4× 39 0.3× 73 1.2k
Zhi Hong Lu United States 19 794 1.8× 339 1.1× 68 0.3× 227 1.2× 192 1.3× 44 1.3k

Countries citing papers authored by Tülin Budak-Alpdoǧan

Since Specialization
Citations

This map shows the geographic impact of Tülin Budak-Alpdoǧan's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Tülin Budak-Alpdoǧan with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Tülin Budak-Alpdoǧan more than expected).

Fields of papers citing papers by Tülin Budak-Alpdoǧan

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Tülin Budak-Alpdoǧan. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Tülin Budak-Alpdoǧan. The network helps show where Tülin Budak-Alpdoǧan may publish in the future.

Co-authorship network of co-authors of Tülin Budak-Alpdoǧan

This figure shows the co-authorship network connecting the top 25 collaborators of Tülin Budak-Alpdoǧan. A scholar is included among the top collaborators of Tülin Budak-Alpdoǧan based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Tülin Budak-Alpdoǧan. Tülin Budak-Alpdoǧan is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Jonnalagadda, Subash C., et al.. (2025). Unlocking nature's potential: Soursop in the battle against resistant acute myeloid leukemia. Biochemistry and Biophysics Reports. 44. 102354–102354.
2.
Gowda, Krishne, Sandeep Kumar Srivastava, Shantu Amin, et al.. (2024). KS18, a Mcl-1 inhibitor, improves the effectiveness of bortezomib and overcomes resistance in refractory multiple myeloma by triggering intrinsic apoptosis. Frontiers in Pharmacology. 15. 1436786–1436786. 2 indexed citations
3.
García, Alexander, et al.. (2024). Isolated AL Amyloidosis of the Colon: A Rare Presentation. ACG Case Reports Journal. 11(2). e01277–e01277.
4.
Nelson, Emily S., et al.. (2024). Discovering Potential in Non-Cancer Medications: A Promising Breakthrough for Multiple Myeloma Patients. Cancers. 16(13). 2381–2381. 1 indexed citations
5.
Jonnalagadda, Subash C., et al.. (2024). Pathways to therapy resistance: The sheltering effect of the bone marrow microenvironment to multiple myeloma cells. Heliyon. 10(12). e33091–e33091. 4 indexed citations
6.
Challagundla, Kishore B., et al.. (2023). Past, Present, and a Glance into the Future of Multiple Myeloma Treatment. Pharmaceuticals. 16(3). 415–415. 14 indexed citations
7.
Schwarting, Roland, et al.. (2022). CD30+ Lymphoproliferative Disorders as Potential Candidates for CD30-Targeted Therapies. Archives of Pathology & Laboratory Medicine. 146(4). 415–432. 4 indexed citations
8.
Singh, J, Sandeep Kumar Srivastava, Krishne Gowda, et al.. (2022). Development of a novel Bruton’s tyrosine kinase inhibitor that exerts anti-cancer activities potentiates response of chemotherapeutic agents in multiple myeloma stem cell-like cells. Frontiers in Pharmacology. 13. 894535–894535. 7 indexed citations
9.
Ferbér, Andres, et al.. (2020). Late-Onset Posttransplant Lymphoproliferative Disorders after Solid Organ Transplantation in Adults: A Case Series and Review of the Literature. SHILAP Revista de lepidopterología. 2020. 1–9. 2 indexed citations
10.
Budak-Alpdoǧan, Tülin, et al.. (2020). Promyelocytic Blast Crisis of Chronic Myeloid Leukemia in a Patient Undergoing Therapy with a Tyrosine Kinase Inhibitor. Cureus. 12(3). e7217–e7217. 2 indexed citations
11.
Zhang, Ping, Shaohua Chang, John Gaughan, et al.. (2018). The Effect of the Histone Deacetylase Inhibitor Suberoylanilide Hydroxamic Acid and Paclitaxel Treatment on Full-Thickness Wound Healing in Mice. Annals of Plastic Surgery. 81(4). 482–486. 7 indexed citations
12.
Lin, Siang-Yo, Sonia Dolfi, Sohrab Amiri, et al.. (2013). P53 regulates the migration of mesenchymal stromal cells in response to the tumor microenvironment through both CXCL12-dependent and -independent mechanisms. International Journal of Oncology. 43(6). 1817–1823. 17 indexed citations
13.
Xie, Xiaoqi, John E. Kerrigan, Tamara Minko, et al.. (2013). Antitumor and modeling studies of a penetratin-peptide that targets E2F-1 in small cell lung cancer. Cancer Biology & Therapy. 14(8). 742–751. 18 indexed citations
14.
Budak-Alpdoǧan, Tülin, et al.. (2009). Retinoblastoma Tumor Suppressor Gene Expression Determines the Response to Sequential Flavopiridol and Doxorubicin Treatment in Small-Cell Lung Carcinoma. Clinical Cancer Research. 15(4). 1232–1240. 7 indexed citations
15.
Longo-Sorbello, Giuseppe S. A., Bobin Chen, Tülin Budak-Alpdoǧan, & Joseph R. Bertino. (2007). Role of Pemetrexed in Non-Small Cell Lung Cancer. Cancer Investigation. 25(1). 59–66. 17 indexed citations
16.
Budak-Alpdoǧan, Tülin, Debabrata Banerjee, & Joseph R. Bertino. (2005). Hematopoietic stem cell gene therapy with drug resistance genes: an update. Cancer Gene Therapy. 12(11). 849–863. 21 indexed citations
17.
O’Connor, Owen A., et al.. (2005). Comparative animal models for the study of lymphohematopoietic tumors: strengths and limitations of present approaches. Leukemia & lymphoma. 46(7). 973–992. 7 indexed citations
18.
Budak-Alpdoǧan, Tülin, Önder Alpdoğan, Debabrata Banerjee, et al.. (2004). Methotrexate and cytarabine inhibit progression of human lymphoma in NOD/SCID mice carrying a mutant dihydrofolate reductase and cytidine deaminase fusion gene. Molecular Therapy. 10(3). 574–584. 16 indexed citations
19.
20.
Budak-Alpdoǧan, Tülin, Zeynep Demirçay, Önder Alpdoğan, et al.. (1997). Behçet's disease in patients with chronic myelogenous leukemia: possible role of interferon-alpha treatment in the occurrence of Behçet's symptoms. Annals of Hematology. 74(1). 45–48. 33 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by John Marken Breakdown of academic impact, for papers by Alessandro Canella Breakdown of academic impact, for papers by Frédéric Barabé Breakdown of academic impact, for papers by Rosa Di Noto Breakdown of academic impact, for papers by Xiaojian Zhu Breakdown of academic impact, for papers by Emma F. Barry Breakdown of academic impact, for papers by Yataro Yoshida Breakdown of academic impact, for papers by S. Danhauser-Riedl Breakdown of academic impact, for papers by Weili Zhao Breakdown of academic impact, for papers by Zhi Hong Lu
Rankless by CCL
2026